PortalPublikationenOutcomes following second allogeneic haematopoietic cell tra...

Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT

Standard

Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. / Nabergoj, Mitja; Mauff, Katya; Robin, Marie; Kröger, Nicolaus; Angelucci, Emanuele; Poiré, Xavier; Passweg, Jakob; Radujkovic, Aleksandar; Platzbecker, Uwe; Robinson, Stephen; Rambaldi, Alessandro; Petersen, Søren Lykke; Stölzel, Fridrich; Stelljes, Matthias; Ciceri, Fabio; Mayer, Jiri; Ladetto, Marco; de Wreede, Liesebeth C; Koster, Linda; Hayden, Patrick J; Czerw, Tomasz; Hernández-Boluda, Juan Carlos; McLornan, Donal; Chalandon, Yves; Yakoub-Agha, Ibrahim.

in: BONE MARROW TRANSPL, Jahrgang 56, Nr. 8, 08.2021, S. 1944-1952.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Nabergoj, M, Mauff, K, Robin, M, Kröger, N, Angelucci, E, Poiré, X, Passweg, J, Radujkovic, A, Platzbecker, U, Robinson, S, Rambaldi, A, Petersen, SL, Stölzel, F, Stelljes, M, Ciceri, F, Mayer, J, Ladetto, M, de Wreede, LC, Koster, L, Hayden, PJ, Czerw, T, Hernández-Boluda, JC, McLornan, D, Chalandon, Y & Yakoub-Agha, I 2021, 'Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT', BONE MARROW TRANSPL, Jg. 56, Nr. 8, S. 1944-1952. https://doi.org/10.1038/s41409-021-01271-4

APA

Nabergoj, M., Mauff, K., Robin, M., Kröger, N., Angelucci, E., Poiré, X., Passweg, J., Radujkovic, A., Platzbecker, U., Robinson, S., Rambaldi, A., Petersen, S. L., Stölzel, F., Stelljes, M., Ciceri, F., Mayer, J., Ladetto, M., de Wreede, L. C., Koster, L., ... Yakoub-Agha, I. (2021). Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. BONE MARROW TRANSPL, 56(8), 1944-1952. https://doi.org/10.1038/s41409-021-01271-4

Vancouver

Nabergoj M, Mauff K, Robin M, Kröger N, Angelucci E, Poiré X et al. Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. BONE MARROW TRANSPL. 2021 Aug;56(8):1944-1952. https://doi.org/10.1038/s41409-021-01271-4

Bibtex

@article{50e33921bb6442f19790daee806c3ad5,
title = "Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT",
abstract = "Therapeutic management of patients with primary or secondary myelofibrosis (MF) who experience relapse or graft failure following allogeneic haematopoietic cell transplantation (allo-HCT) remains heterogeneous. We retrospectively analyzed 216 patients undergoing a second allo-HCT for either relapse (56%) or graft failure (31%) between 2010 and 2017. Median age was 57.3 years (range 51-63). The same donor as for the first allo-HCT was chosen in 66 patients (31%) of whom 19 received an HLA-identical sibling donor, whereas a different donor was chosen for 116 patients (54%). Median follow-up was 40 months. Three-year overall survival (OS) and relapse-free survival (RFS) were 42% and 39%, respectively. Three-year non-relapse mortality (NRM) and relapse rates were 36% and 25%, respectively. Grade II-IV and III-IV acute GVHD occurred in 25% and 11% of patients, respectively, and the 3-year incidence of chronic GVHD was 33% including 14% for extensive grade. Graft-failure incidence at 1 year was 14%. In conclusion, our data suggest that a second allo-HCT is a potential option for patients failing first allo-HCT for MF albeit careful patient assessment is fundamental to identify individual patients who could benefit from this approach.",
author = "Mitja Nabergoj and Katya Mauff and Marie Robin and Nicolaus Kr{\"o}ger and Emanuele Angelucci and Xavier Poir{\'e} and Jakob Passweg and Aleksandar Radujkovic and Uwe Platzbecker and Stephen Robinson and Alessandro Rambaldi and Petersen, {S{\o}ren Lykke} and Fridrich St{\"o}lzel and Matthias Stelljes and Fabio Ciceri and Jiri Mayer and Marco Ladetto and {de Wreede}, {Liesebeth C} and Linda Koster and Hayden, {Patrick J} and Tomasz Czerw and Hern{\'a}ndez-Boluda, {Juan Carlos} and Donal McLornan and Yves Chalandon and Ibrahim Yakoub-Agha",
note = "{\textcopyright} 2021. The Author(s), under exclusive licence to Springer Nature Limited.",
year = "2021",
month = aug,
doi = "10.1038/s41409-021-01271-4",
language = "English",
volume = "56",
pages = "1944--1952",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "8",

}

RIS

TY - JOUR

T1 - Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT

AU - Nabergoj, Mitja

AU - Mauff, Katya

AU - Robin, Marie

AU - Kröger, Nicolaus

AU - Angelucci, Emanuele

AU - Poiré, Xavier

AU - Passweg, Jakob

AU - Radujkovic, Aleksandar

AU - Platzbecker, Uwe

AU - Robinson, Stephen

AU - Rambaldi, Alessandro

AU - Petersen, Søren Lykke

AU - Stölzel, Fridrich

AU - Stelljes, Matthias

AU - Ciceri, Fabio

AU - Mayer, Jiri

AU - Ladetto, Marco

AU - de Wreede, Liesebeth C

AU - Koster, Linda

AU - Hayden, Patrick J

AU - Czerw, Tomasz

AU - Hernández-Boluda, Juan Carlos

AU - McLornan, Donal

AU - Chalandon, Yves

AU - Yakoub-Agha, Ibrahim

N1 - © 2021. The Author(s), under exclusive licence to Springer Nature Limited.

PY - 2021/8

Y1 - 2021/8

N2 - Therapeutic management of patients with primary or secondary myelofibrosis (MF) who experience relapse or graft failure following allogeneic haematopoietic cell transplantation (allo-HCT) remains heterogeneous. We retrospectively analyzed 216 patients undergoing a second allo-HCT for either relapse (56%) or graft failure (31%) between 2010 and 2017. Median age was 57.3 years (range 51-63). The same donor as for the first allo-HCT was chosen in 66 patients (31%) of whom 19 received an HLA-identical sibling donor, whereas a different donor was chosen for 116 patients (54%). Median follow-up was 40 months. Three-year overall survival (OS) and relapse-free survival (RFS) were 42% and 39%, respectively. Three-year non-relapse mortality (NRM) and relapse rates were 36% and 25%, respectively. Grade II-IV and III-IV acute GVHD occurred in 25% and 11% of patients, respectively, and the 3-year incidence of chronic GVHD was 33% including 14% for extensive grade. Graft-failure incidence at 1 year was 14%. In conclusion, our data suggest that a second allo-HCT is a potential option for patients failing first allo-HCT for MF albeit careful patient assessment is fundamental to identify individual patients who could benefit from this approach.

AB - Therapeutic management of patients with primary or secondary myelofibrosis (MF) who experience relapse or graft failure following allogeneic haematopoietic cell transplantation (allo-HCT) remains heterogeneous. We retrospectively analyzed 216 patients undergoing a second allo-HCT for either relapse (56%) or graft failure (31%) between 2010 and 2017. Median age was 57.3 years (range 51-63). The same donor as for the first allo-HCT was chosen in 66 patients (31%) of whom 19 received an HLA-identical sibling donor, whereas a different donor was chosen for 116 patients (54%). Median follow-up was 40 months. Three-year overall survival (OS) and relapse-free survival (RFS) were 42% and 39%, respectively. Three-year non-relapse mortality (NRM) and relapse rates were 36% and 25%, respectively. Grade II-IV and III-IV acute GVHD occurred in 25% and 11% of patients, respectively, and the 3-year incidence of chronic GVHD was 33% including 14% for extensive grade. Graft-failure incidence at 1 year was 14%. In conclusion, our data suggest that a second allo-HCT is a potential option for patients failing first allo-HCT for MF albeit careful patient assessment is fundamental to identify individual patients who could benefit from this approach.

U2 - 10.1038/s41409-021-01271-4

DO - 10.1038/s41409-021-01271-4

M3 - SCORING: Journal article

C2 - 33824436

VL - 56

SP - 1944

EP - 1952

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 8

ER -